Other Indications

There is evidence to support the use of APPA in other indications, some of which have particularly high value.

Alzheimer’s Disease

In addition to APPA’s applicability in OA, there is an increasing view that inflammation, in particular driven via NFkB, plays a pivotal role in the development of Alzheimer ’s disease (AD). AKLRD is planning to explore the use of APPA as an anti-inflammatory treatment for AD, driven by reported improvements in cognition in a handful of AD patients taking APPA for OA. An eminent clinical AD expert believes that APPA is a suitable candidate for a Phase II 18-month AD study. Following a science advice meeting, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has also indicated support.

Rheumatoid Arthritis

Ongoing research into the anti-inflammatory mode of action of APPA has shown APPA could be a viable candidate in a subset of rheumatoid arthritis patients, a market where pricing is attractive.